{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:24:53Z","timestamp":1779099893789,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nimotuzumab, a humanized immunoglobulin G1 monoclonal antibody, is mainly used in combination with radiotherapy for the treatment of stage III\/IV nasopharyngeal carcinoma (NPC) or locally advanced head and neck squamous-cell carcinoma (HNSCC) with positive epidermal growth factor receptor (EGFR) expression. Although the drug has a favorable safety profile, it is associated with various adverse reactions, among which hypotension is relatively uncommon. Clinically, hypotension caused by nimotuzumab mainly manifests as mild blood pressure (BP) reduction, which can be relieved via rest. This case reports a 65-year-old male patient with advanced NPC who developed severe persistent hypotension after receiving radiotherapy combined with 5 cycles of nimotuzumab treatment. After excluding related factors such as cardiac function, endocrine function, thyroid function, inflammatory factors and other drugs, the adverse reaction was considered to be closely associated with nimotuzumab. After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient\u2019s BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1807371","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:01:18Z","timestamp":1773817278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenhui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guilin People\u2019s Hospital","place":["Guilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Center for Clinical Trial and Research, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"110649","DOI":"10.1016\/j.biopha.2020.110649","article-title":"Anti-EGFR therapies in nasopharyngeal carcinoma","volume":"131","author":"Chen","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e37853","DOI":"10.1097\/MD.0000000000037853","article-title":"Nasopharyngeal carcinoma with leptomeningeal metastases has been treated with comprehensive treatment for long-term survival: A case report and literature review","volume":"103","author":"Yang","year":"2024","journal-title":"Med (United States)"},{"key":"B4","article-title":"Nimotuzumab package insert. Retrieved from National Medical Products Administration (NMPA) Drug Database","year":"2024"},{"key":"B5","article-title":"Common terminology criteria for adverse events (CTCAE).v.5.0","volume":"155","year":"2017","journal-title":"Cancer Ther Eval Progr"},{"key":"B6","first-page":"897","article-title":"Advances in the drug diagnosis reactions of adverse","volume-title":"J Clin Pharmacol","author":"Naranjo","year":"1992"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.23750\/ABM.V88I3.6138","article-title":"Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review","volume":"88","author":"Pellegrino","year":"2017","journal-title":"Acta Biomed"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000085619","article-title":"A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer","volume":"51","author":"Mori","year":"2005","journal-title":"Chemotherapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2025.2597064","article-title":"Cytokine release syndrome complicated with sepsis induced by tislelizumab in a patient with advanced hepatocellular carcinoma: A case report","volume":"21","author":"Chu","year":"2025","journal-title":"Hum Vaccines Immunother"},{"key":"B10","doi-asserted-by":"crossref","unstructured":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin\n          \n          \n            \n              Ramakrishnan\n              MS\n            \n            \n              Eswaraiah\n              A\n            \n            \n              Crombet\n              T\n            \n            \n              Piedra\n              P\n            \n            \n              Saurez\n              G\n            \n            \n              Iyer\n              H\n            \n          \n          10.4161\/mabs.1.1.7509\n          20046573\n          MAbs\n          1\n          2009","DOI":"10.4161\/mabs.1.1.7509"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1242","article-title":"Management of infusion reactions associated with cetuximab treatment: A case report","volume":"6","author":"Ohshita","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1009-6","article-title":"Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer","volume":"65","author":"Saif","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B14","article-title":"Cetuximab-associated infusion reactions: pathology and management","volume":"20","author":"Patel","year":"2006","journal-title":"Oncol (Williston Park)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1042\/CS20150503","article-title":"Consequences of postnatal vascular smooth muscle EGFR deletion on acute angiotensin II action","volume":"130","author":"Schreier","year":"2016","journal-title":"Clin Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am J Physiol - Cell Physiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-070115-095427.EGFR","article-title":"EGFR transactivation: mechanisms, pathophysiology and potential therapies in cardiovascular system","volume":"56","author":"Forrester","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10647","article-title":"Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody","volume":"101","author":"Crombet-Ramos","year":"2002","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients","volume":"22","author":"Crombet","year":"2004","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X18823447","article-title":"Anaphylactoid hypersensitivity reaction from intra-arterial cetuximab: Clinical considerations and management","volume":"7","author":"Bardash","year":"2019","journal-title":"SAGE Open Med Case Rep"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1875677","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:53:16Z","timestamp":1779097996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1807371"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807371","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1807371"}}